Susquehanna International Group
NRIX icon

Susquehanna International Group’s Nurix Therapeutics NRIX Stock Holding History

Susquehanna International Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.32M Buy
214,000
+29,600
+16% +$491K ﹤0.01% 5060
2025
Q4 		$3.5M Buy
184,400
+113,800
+161% +$1.63M ﹤0.01% 4606
2025
Q3 		$652K Sell
70,600
-15,100
-18% -$157K ﹤0.01% 8371
2025
Q2 		$976K Buy
85,700
+34,600
+68% +$374K ﹤0.01% 7500
2025
Q1 		$607K Sell
51,100
-236,900
-82% -$3.96M ﹤0.01% 8476
2024
Q4 		$5.43M Buy
288,000
+226,300
+367% +$5.19M ﹤0.01% 3466
2024
Q3 		$1.39M Buy
61,700
+30,500
+98% +$691K ﹤0.01% 6089
2024
Q2 		$651K Buy
31,200
+2,100
+7% +$32.7K ﹤0.01% 7607
2024
Q1 		$428K Buy
29,100
+10,200
+54% +$110K ﹤0.01% 8887
2023
Q4 		$195K Buy
+18,900
New +$130K ﹤0.01% 10717
2023
Q3 		– Sell
-93,300
Closed -$932K – 12645
2023
Q2 		$932K Buy
93,300
+4,200
+5% +$42.8K ﹤0.01% 6854
2023
Q1 		$791K Buy
89,100
+72,800
+447% +$759K ﹤0.01% 7440
2022
Q4 		$179K Sell
16,300
-35,300
-68% -$426K ﹤0.01% 10285
2022
Q3 		$672K Sell
51,600
-3,900
-7% -$61.7K ﹤0.01% 7680
2022
Q2 		$703K Sell
55,500
-900
-2% -$10.2K ﹤0.01% 7418
2022
Q1 		$790K Buy
+56,400
New +$1M ﹤0.01% 7752

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Susquehanna International Group's NRIX Position: Q1 2026 in Review

Susquehanna International Group increased its Nurix Therapeutics (NRIX) stake by 61% in Q1 2026, buying an estimated $512K and bringing the position to 81,455 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #7299.

Susquehanna International Group first reported a position in NRIX in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.77M in Q1 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Susquehanna International Group held 81,455 shares of Nurix Therapeutics worth $1.26M as of Q1 2026.
  • Susquehanna International Group bought 30,902 Nurix Therapeutics shares in Q1 2026, an estimated $512K.
  • Nurix Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7299 holding.
  • Susquehanna International Group first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Susquehanna International Group's Nurix Therapeutics position peaked at $1.77M in Q1 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.